Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Clinical features and treatment of COVID-19 patients in northeast Chongqing

© 2020 Wiley Periodicals, Inc.

The outbreak of the novel coronavirus in China (SARS-CoV-2) that began in December 2019 presents a significant and urgent threat to global health. This study was conducted to provide the international community with a deeper understanding of this new infectious disease. Epidemiological, clinical features, laboratory findings, radiological characteristics, treatment, and clinical outcomes of 135 patients in northeast Chongqing were collected and analyzed in this study. A total of 135 hospitalized patients with COVID-19 were enrolled. The median age was 47 years (interquartile range, 36-55), and there was no significant gender difference (53.3% men). The majority of patients had contact with people from the Wuhan area. Forty-three (31.9%) patients had underlying disease, primarily hypertension (13 [9.6%]), diabetes (12 [8.9%]), cardiovascular disease (7 [5.2%]), and malignancy (4 [3.0%]). Common symptoms included fever (120 [88.9%]), cough (102 [76.5%]), and fatigue (44 [32.5%]). Chest computed tomography scans showed bilateral patchy shadows or ground glass opacity in the lungs of all the patients. All patients received antiviral therapy (135 [100%]) (Kaletra and interferon were both used), antibacterial therapy (59 [43.7%]), and corticosteroids (36 [26.7%]). In addition, many patients received traditional Chinese medicine (TCM) (124 [91.8%]). It is suggested that patients should receive Kaletra early and should be treated by a combination of Western and Chinese medicines. Compared to the mild cases, the severe ones had lower lymphocyte counts and higher plasma levels of Pt, APTT, d-dimer, lactate dehydrogenase, PCT, ALB, C-reactive protein, and aspartate aminotransferase. This study demonstrates the clinic features and therapies of 135 COVID-19 patients. Kaletra and TCM played an important role in the treatment of the viral pneumonia. Further studies are required to explore the role of Kaletra and TCM in the treatment of COVID... Full description

Year of Publication: 2020
Contained in: Journal of medical virology Vol. 92, No. 7 (2020), p. 797-806
All journal articles: Search for all articles in this journal
Language: English
Contributors: Wan, Suxin | Author
Xiang, Yi
Fang, Wei
Zheng, Yu
Li, Boqun
Hu, Yanjun
Lang, Chunhui
Huang, Daoqiu
Sun, Qiuyan
Xiong, Yan
Huang, Xia
Lv, Jinglong
Luo, Yaling
Shen, Li
Yang, Haoran
Huang, Gu
Yang, Ruishan
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: 2494G1JF75
9008-11-1
COVID-19
Journal Article
O3J8G9O825
Research Support, Non-U.S. Gov't
clinical features
cognition
lopinavir-ritonavir drug combination
northeast Chongqing
treatment
Additional Keywords: Adolescent
Adrenal Cortex Hormones
Adult
Aged
Anti-Bacterial Agents
Antiviral Agents
Betacoronavirus
Biomarkers
Cardiovascular Diseases
China
Clinical Laboratory Techniques
Coronavirus Infections
Cough
Diabetes Complications
Diabetes Mellitus
Drug Combinations
Drugs, Chinese Herbal
Fatigue
Female
Fever
Humans
Interferons
Lopinavir
Male
Middle Aged
Neoplasms
Pandemics
Pneumonia, Viral
Retrospective Studies
Ritonavir
Severity of Illness Index
Tomography, X-Ray Computed
ISSN: 1096-9071
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Completed 24.06.2020
Date Revised 24.06.2020
published: Print-Electronic
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32198776
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1002/jmv.25783
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 07219nma a2201417 c 4500
001 NLM308690796
003 DE-601
005 20200625213605.0
007 cr uuu---uuuuu
008 200330s2020 000 0 eng d
024 7 |a 10.1002/jmv.25783  |2 doi 
028 5 2 |a pubmed20n1245.xml 
035 |a (DE-599)NLM32198776 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Wan, Suxin 
245 1 0 |a Clinical features and treatment of COVID-19 patients in northeast Chongqing  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Date Completed 24.06.2020 
500 |a Date Revised 24.06.2020 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a © 2020 Wiley Periodicals, Inc. 
520 |a The outbreak of the novel coronavirus in China (SARS-CoV-2) that began in December 2019 presents a significant and urgent threat to global health. This study was conducted to provide the international community with a deeper understanding of this new infectious disease. Epidemiological, clinical features, laboratory findings, radiological characteristics, treatment, and clinical outcomes of 135 patients in northeast Chongqing were collected and analyzed in this study. A total of 135 hospitalized patients with COVID-19 were enrolled. The median age was 47 years (interquartile range, 36-55), and there was no significant gender difference (53.3% men). The majority of patients had contact with people from the Wuhan area. Forty-three (31.9%) patients had underlying disease, primarily hypertension (13 [9.6%]), diabetes (12 [8.9%]), cardiovascular disease (7 [5.2%]), and malignancy (4 [3.0%]). Common symptoms included fever (120 [88.9%]), cough (102 [76.5%]), and fatigue (44 [32.5%]). Chest computed tomography scans showed bilateral patchy shadows or ground glass opacity in the lungs of all the patients. All patients received antiviral therapy (135 [100%]) (Kaletra and interferon were both used), antibacterial therapy (59 [43.7%]), and corticosteroids (36 [26.7%]). In addition, many patients received traditional Chinese medicine (TCM) (124 [91.8%]). It is suggested that patients should receive Kaletra early and should be treated by a combination of Western and Chinese medicines. Compared to the mild cases, the severe ones had lower lymphocyte counts and higher plasma levels of Pt, APTT, d-dimer, lactate dehydrogenase, PCT, ALB, C-reactive protein, and aspartate aminotransferase. This study demonstrates the clinic features and therapies of 135 COVID-19 patients. Kaletra and TCM played an important role in the treatment of the viral pneumonia. Further studies are required to explore the role of Kaletra and TCM in the treatment of COVID-19 
611 2 7 |a Journal Article  |2 gnd 
611 2 7 |a Research Support, Non-U.S. Gov't  |2 gnd 
653 2 |a Adolescent  |6 D000293 
653 2 |a Adrenal Cortex Hormones  |6 D000305  |a therapeutic use  |6 Q000627 
653 2 |a Adult  |6 D000328 
653 2 |a Aged  |6 D000368 
653 2 |a Anti-Bacterial Agents  |6 D000900  |a therapeutic use  |6 Q000627 
653 2 |a Antiviral Agents  |6 D000998  |a *therapeutic use  |6 Q000627 
653 2 |a Betacoronavirus  |6 D000073640  |a isolation & purification  |6 Q000302  |a *pathogenicity  |6 Q000472 
653 2 |a Biomarkers  |6 D015415  |a blood  |6 Q000097 
653 2 |a Cardiovascular Diseases  |6 D002318  |a complications  |6 Q000150  |a diagnosis  |6 Q000175  |a *drug therapy  |6 Q000188  |a pathology  |6 Q000473 
653 2 |a China  |6 D002681 
653 2 |a Clinical Laboratory Techniques  |6 D019411  |a methods  |6 Q000379 
653 2 |a Coronavirus Infections  |6 D018352  |a complications  |6 Q000150  |a diagnosis  |6 Q000175  |a *drug therapy  |6 Q000188  |a pathology  |6 Q000473 
653 2 |a Cough  |6 D003371  |a diagnosis  |6 Q000175  |a physiopathology  |6 Q000503  |a virology  |6 Q000821 
653 2 |a Diabetes Complications  |6 D048909  |a blood  |6 Q000097  |a *drug therapy  |6 Q000188 
653 2 |a Diabetes Mellitus  |6 D003920  |a diagnosis  |6 Q000175  |a *drug therapy  |6 Q000188  |a pathology  |6 Q000473 
653 2 |a Drug Combinations  |6 D004338 
653 2 |a Drugs, Chinese Herbal  |6 D004365  |a therapeutic use  |6 Q000627 
653 2 |a Fatigue  |6 D005221  |a diagnosis  |6 Q000175  |a physiopathology  |6 Q000503  |a virology  |6 Q000821 
653 2 |a Female  |6 D005260 
653 2 |a Fever  |6 D005334  |a diagnosis  |6 Q000175  |a physiopathology  |6 Q000503  |a virology  |6 Q000821 
653 2 |a Humans  |6 D006801 
653 2 |a Interferons  |6 D007372  |a therapeutic use  |6 Q000627 
653 2 |a Lopinavir  |6 D061466  |a therapeutic use  |6 Q000627 
653 2 |a Male  |6 D008297 
653 2 |a Middle Aged  |6 D008875 
653 2 |a Neoplasms  |6 D009369  |a complications  |6 Q000150  |a diagnosis  |6 Q000175  |a *drug therapy  |6 Q000188  |a pathology  |6 Q000473 
653 2 |a Pandemics  |6 D058873 
653 2 |a Pneumonia, Viral  |6 D011024  |a complications  |6 Q000150  |a diagnosis  |6 Q000175  |a *drug therapy  |6 Q000188  |a pathology  |6 Q000473 
653 2 |a Retrospective Studies  |6 D012189 
653 2 |a Ritonavir  |6 D019438  |a therapeutic use  |6 Q000627 
653 2 |a Severity of Illness Index  |6 D012720 
653 2 |a Tomography, X-Ray Computed  |6 D014057 
655 7 |a COVID-19  |2 gnd 
655 7 |a clinical features  |2 gnd 
655 7 |a cognition  |2 gnd 
655 7 |a northeast Chongqing  |2 gnd 
655 7 |a treatment  |2 gnd 
655 7 |a Adrenal Cortex Hormones  |2 gnd 
655 7 |a Anti-Bacterial Agents  |2 gnd 
655 7 |a Antiviral Agents  |2 gnd 
655 7 |a Biomarkers  |2 gnd 
655 7 |a Drug Combinations  |2 gnd 
655 7 |a Drugs, Chinese Herbal  |2 gnd 
655 7 |a lopinavir-ritonavir drug combination  |2 gnd 
655 7 |a Lopinavir  |2 gnd 
655 7 |a 2494G1JF75  |2 gnd 
655 7 |a Interferons  |2 gnd 
655 7 |a 9008-11-1  |2 gnd 
655 7 |a Ritonavir  |2 gnd 
655 7 |a O3J8G9O825  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 1 |A f  |a Research Support, Non-U.S. Gov't 
689 0 |5 DE-601 
689 1 0 |a COVID-19 
689 1 1 |a clinical features 
689 1 2 |a cognition 
689 1 3 |a northeast Chongqing 
689 1 4 |a treatment 
689 1 |5 DE-601 
689 2 0 |a Adrenal Cortex Hormones 
689 2 1 |a Anti-Bacterial Agents 
689 2 2 |a Antiviral Agents 
689 2 3 |a Biomarkers 
689 2 4 |a Drug Combinations 
689 2 5 |a Drugs, Chinese Herbal 
689 2 6 |a lopinavir-ritonavir drug combination 
689 2 7 |a Lopinavir 
689 2 8 |A r  |a 2494G1JF75 
689 2 9 |a Interferons 
689 2 X |A r  |a 9008-11-1 
689 2 X |a Ritonavir 
689 2 X |A r  |a O3J8G9O825 
689 2 |5 DE-601 
700 1 |a Xiang, Yi 
700 1 |a Fang, Wei 
700 1 |a Zheng, Yu 
700 1 |a Li, Boqun 
700 1 |a Hu, Yanjun 
700 1 |a Lang, Chunhui 
700 1 |a Huang, Daoqiu 
700 1 |a Sun, Qiuyan 
700 1 |a Xiong, Yan 
700 1 |a Huang, Xia 
700 1 |a Lv, Jinglong 
700 1 |a Luo, Yaling 
700 1 |a Shen, Li 
700 1 |a Yang, Haoran 
700 1 |a Huang, Gu 
700 1 |a Yang, Ruishan 
773 0 8 |i in  |t Journal of medical virology  |g Vol. 92, No. 7 (2020), p. 797-806  |q 92:7<797-806  |w (DE-601)NLM000285676  |x 1096-9071 
856 4 1 |u http://dx.doi.org/10.1002/jmv.25783  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 92  |j 2020  |e 7  |b 20  |c 07  |h 797-806